Lung cancer is among the most common cancers and is the leading cause of cancer related deaths. Lung cancer includes two different histological subtypes, non-small cell lung cancer and small cell lung cancer, which behaves differently and is managed differently. The chapter aims in understanding how to clinically evaluate and work up a patient with carcinoma lung. The practical radiation planning aspects and dose fractionations are also discussed. Two clinical scenarios: one patient with non-small cell lung cancer and another with small cell lung cancer are also discussed.
KeywordsNon-small cell lung cancer Small cell lung cancer Radiotherapy Stereotactic radiotherapy
- 1.Rengan R, Chetty IJ, Decker R, Langer CJ, O’Meara WP, Perez MB. Brady’s principles and practice of radiation oncology. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Lung cancer. 6th ed. Philadelphia: Wolters Kluwer/LWW; 2013. p. 938–73.Google Scholar
- 4.Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52(2):137–48.CrossRefGoogle Scholar
- 5.Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;100:76–85. https://doi.org/10.1016/j.radonc.2011.06.031.CrossRefPubMedGoogle Scholar
- 7.Rodrigues G, Choy H, Bradley J, et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015;5:141–8. https://doi.org/10.1016/j.prro.2015.02.012.CrossRefPubMedGoogle Scholar
- 12.Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT study team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25. https://doi.org/10.1016/S1470-2045(17)30318-2.CrossRefPubMedPubMedCentralGoogle Scholar